Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03218241 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote
A Phase 1 study, sponsored by Portola Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT03218241 is a Phase 1 study that has completed, run by Portola Pharmaceuticals. The registered enrollment target is 32 participants.
The verdict
NCT03218241, a Phase 1 study, has completed, sponsored by Portola Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a single center, double-blind, randomized, placebo-controlled, ascending, single dose study of PRT064445 or its matching placebo, in healthy subjects.
Interventions
- DRUG Placebo
- BIOLOGICAL PRT064445
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2012-06 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03218241
The ClinicalTrials.gov registry entry for NCT03218241 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Portola Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03218241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03218241 about?
NCT03218241 is a clinical study titled "Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote". This is a single center, double-blind, randomized, placebo-controlled, ascending, single dose study of PRT064445 or its matching placebo, in healthy subjects.
What is the current status of trial NCT03218241?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2012-06. Estimated completion is 2012-10.
What interventions are being tested in trial NCT03218241?
The interventions under investigation include: Placebo (DRUG), PRT064445 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03218241?
This trial is sponsored by Portola Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.